A Phase 1 Open-label Study to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics, Safety and Tolerability of Gilteritinib Compared to Healthy Participants With Normal Renal Function
Latest Information Update: 19 Jul 2023
At a glance
- Drugs Gilteritinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Pharmacokinetics
- Sponsors Astellas Pharma Global Development
- 07 Nov 2022 Status changed from active, no longer recruiting to completed.
- 18 Sep 2022 Planned End Date changed from 31 Aug 2022 to 31 Mar 2023.
- 18 Sep 2022 Planned primary completion date changed from 31 Aug 2022 to 31 Mar 2023.